Lataa...

Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?

Erlotinib, an epidermal growth factor receptor and tyrosine kinase inhibitor, is a targeted drug that was approved for the treatment of non-small-cell lung cancers and pancreatic cancers. Targeted tyrosine kinase inhibitors are known to have cardiotoxic effects. However, erlotinib does not have a st...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Onco Targets Ther
Päätekijät: Kus, Tulay, Aktas, Gokmen, Sevinc, Alper, Kalender, Mehmet Emin, Camci, Celaletdin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2015
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485179/
https://ncbi.nlm.nih.gov/pubmed/26150726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S84480
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!